Hill-Rom (HRC) to Release Quarterly Earnings on Friday
Hill-Rom (NYSE:HRC) will issue its quarterly earnings data before the market opens on Friday, January 25th. Analysts expect the company to announce earnings of $0.98 per share for the quarter.
Hill-Rom (NYSE:HRC) last released its quarterly earnings results on Friday, November 2nd. The medical technology company reported $1.63 earnings per share for the quarter, topping analysts’ consensus estimates of $1.51 by $0.12. The company had revenue of $759.20 million during the quarter, compared to analysts’ expectations of $750.90 million. Hill-Rom had a return on equity of 21.10% and a net margin of 8.86%. Hill-Rom’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.32 EPS. On average, analysts expect Hill-Rom to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.
NYSE HRC opened at $96.16 on Thursday. The stock has a market capitalization of $6.55 billion, a P/E ratio of 20.24, a price-to-earnings-growth ratio of 1.37 and a beta of 0.96. Hill-Rom has a twelve month low of $78.16 and a twelve month high of $99.81. The company has a quick ratio of 1.30, a current ratio of 1.74 and a debt-to-equity ratio of 1.11.
In other Hill-Rom news, SVP Andreas G. Frank sold 7,454 shares of the stock in a transaction that occurred on Wednesday, November 28th. The stock was sold at an average price of $95.76, for a total transaction of $713,795.04. Following the completion of the transaction, the senior vice president now owns 27,224 shares of the company’s stock, valued at $2,606,970.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.90% of the stock is owned by corporate insiders.
A number of equities analysts recently weighed in on the company. ValuEngine raised Hill-Rom from a “hold” rating to a “buy” rating in a report on Saturday, January 19th. Zacks Investment Research cut Hill-Rom from a “hold” rating to a “sell” rating in a report on Wednesday, January 16th. Morgan Stanley reduced their price target on Hill-Rom from $100.00 to $98.00 and set an “equal weight” rating for the company in a report on Wednesday, January 2nd. Finally, UBS Group assumed coverage on Hill-Rom in a report on Tuesday, November 27th. They issued a “buy” rating and a $115.00 price target for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. Hill-Rom has an average rating of “Buy” and a consensus target price of $102.67.
COPYRIGHT VIOLATION WARNING: “Hill-Rom (HRC) to Release Quarterly Earnings on Friday” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://theolympiareport.com/2019/01/24/hill-rom-hrc-to-release-quarterly-earnings-on-friday.html.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Featured Article: How Do Front-End Loads Impact an Investment?
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.